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ABSTRACTS

positive FOBT, and again edema in the right facial region. EBV reac-

scenarios where individuals are vaccinated with RZV versus no HZ vac-

tivation was suspected, for which a viral load was requested with a

cine. The base-case analysis modeled HSCT recipients, with scenario ana-

report of 1 353.25 copies/ml. We administrated a second dose of

lyses included for patients with either Hodgkin lymphoma or breast

rituximab, however, the patient persisted with gastrointestinal bleeding,

cancer. To represent younger populations, the model followed 35-year-

which led to hypovolemic shock and death.Conclusion(s): PTLD have

old HSCT recipients who were assumed to remain IC for five years.

an OS of 40-60% (5years), due to the fact that patients die because of

Patients with Hodgkin lymphoma or breast cancer were aged 25 and

disease progression and infectious complications. This case reflects the

45 years, respectively, and remained IC for two years. The model

complexity of following a treatment schedule, especially when infec-

assumed 100% compliance with the two-dose RZV series. RZV efficacy

tious complications overlap with the application of rituximab, which

and waning inputs were derived from phase 3 clinical trial data. Other

allowed EBV replication, with consequent disease progression.

input values for epidemiological, cost, utility, and mortality parameters
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2,098 QALYs gained for patients with Hodgkin lymphoma and
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136,399 avoided HZ cases and 1,813 QALYs gained for patients with

Cost-Effectiveness Analysis of Recombinant Zoster

Vaccine for the Prevention of Herpes Zoster in

breast cancer. From the societal perspective, incremental cost-

Immunocompromised Adults Diagnosed with Select Cancers in the

effectiveness ratios (ICERs) for RZV vaccination were $95,972/QALY

United States

gained for Hodgkin lymphoma and $67,682 for breast cancer. For the
HSCT population, ~97% of simulations from the probabilistic sensitiv1
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ity analysis demonstrated ICERs less than $100,000/QALY gained.
Conclusion(s): Although the risk and burden of HZ are increased in
individuals diagnosed with cancer over a relatively short period,
results from this study highlight the value of RZV in preventing HZ
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Introduction / Background / Significance: Immunocompromised
(IC) populations diagnosed with cancer are at increased risk for herpes
zoster (HZ) due to their underlying disease and/or therapy. This risk is
highest among individuals receiving hematopoietic stem cell transplant (HSCT) to treat multiple myeloma, lymphomas, or other diseases.
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HZ is characterized by a painful vesicular rash. IC populations with HZ
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ter vaccine (RZV) versus no vaccine for the prevention of HZ in IC
adult HSCT recipients, patients with Hodgkin lymphoma, and patients

Background: Large granular lymphocytes (LGLs), comprising highly

with breast cancer in the United States (US).

differentiated CD8+ cytotoxic T (Tc) cells, are expanded and patho-

Materials and Methods / Case Presentation / Objective: A Markov

genic in T cell large granular lymphocytic leukemia (T-LGLL). Killer cell

model was developed to simulate a hypothetical cohort of 1 million IC

lectin-like receptor G1 (KLRG1) is a surface receptor that marks these

adults over a 30-year period. The model uses a one-year cycle length and

highly differentiated Tc cells. ABC008, a humanized afucosylated anti-

estimates avoided HZ cases and complications, discounted quality-

KLRG1 monoclonal antibody, potently depletes KLRG1+ T cells

adjusted life-years (QALYs) gained, and discounted costs, comparing

in vitro and in cynomolgus monkeys. ABC008 is under development

